Loncar Cancer Immunotherapy ETF (CNCR) Reaches $25.01 Formed H&S; Terreno Realty (TRNO) Has 1.33 Sentiment

Terreno Realty Corp (TRNO) investors sentiment decreased to 1.33 in Q1 2018. It’s down -0.15, from 1.48 in 2017Q4. The ratio dived, as 80 active investment managers started new and increased stock positions, while 60 cut down and sold their stock positions in Terreno Realty Corp. The active investment managers in our database now hold: 51.35 million shares, up from 50.69 million shares in 2017Q4. Also, the number of active investment managers holding Terreno Realty Corp in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 16 Reduced: 44 Increased: 60 New Position: 20.

Loncar Cancer Immunotherapy ETF (CNCR) formed H&S with $24.26 target or 3.00% below today’s $25.01 share price. Loncar Cancer Immunotherapy ETF (CNCR) has $70.29 million valuation. The ETF decreased 2.50% or $0.64 during the last trading session, reaching $25.01. About 38,181 shares traded. Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) has risen 25.36% since June 26, 2017 and is uptrending. It has outperformed by 12.79% the S&P500.

Terreno Realty Corporation is a real estate investment trust. The company has market cap of $2.07 billion. The firm invests in real estate markets of the United States. It has a 36.81 P/E ratio. It acquires, owns and operates industrial properties in six major coastal U.S. markets.

Since January 1, 0001, it had 1 insider buy, and 0 sales for $208,835 activity.

Terreno Realty Corporation (NYSE:TRNO) Institutional Positions Chart